{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:38:55Z","timestamp":1790156335356,"version":"4.0.1"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":703,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jbo.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T15:01:50Z","timestamp":1358434910000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Incidence and consequences of bone metastases in lung cancer patients"],"prefix":"10.1016","volume":"2","author":[{"given":"Michael","family":"Kuchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina L.","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Kuchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Wheatley-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2012.12.004_bib1","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.jbo.2012.12.004_bib2","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1634\/theoncologist.2011-0079","article-title":"Impact of new chemotherapeutic and targeted agents on survival in stage IV non-small cell lung cancer","volume":"16","author":"Yu","year":"2011","journal-title":"The Oncologist"},{"key":"10.1016\/j.jbo.2012.12.004_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","article-title":"Skeletal metastases in non-small cell lung cancer: a retrospective study","volume":"57","author":"Tsuya","year":"2007","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jbo.2012.12.004_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0003-4975(96)00220-2","article-title":"Distribution of distant metastases from newly diagnosed non-small cell lung cancer","volume":"62","author":"Quint","year":"1996","journal-title":"The Annals of Thoracic Surgery"},{"key":"10.1016\/j.jbo.2012.12.004_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/02841869709001267","article-title":"Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung\u2014a study from a cohort of 259 consecutive patients treated with chemotherapy","volume":"36","author":"Stenbygaard","year":"1997","journal-title":"Acta Oncologica (Stockholm, Sweden)"},{"key":"10.1016\/j.jbo.2012.12.004_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00266372","article-title":"Metastatic bone disease from occult carcinoma: a profile","volume":"13","author":"Nottebaert","year":"1989","journal-title":"International Orthopaedics"},{"key":"10.1016\/j.jbo.2012.12.004_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2010.04.003","article-title":"Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases","volume":"71","author":"Sun","year":"2011","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jbo.2012.12.004_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"key":"10.1016\/j.jbo.2012.12.004_bib9","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","article-title":"Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601)","volume":"6","author":"Decroisette","year":"2011","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib11","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2354.2009.01135.x","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"European Journal of Cancer Care"},{"key":"10.1016\/j.jbo.2012.12.004_bib12","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/01243894-200607000-00012","article-title":"Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer","volume":"1","author":"Delea","year":"2006","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib13","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib14","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","article-title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications","volume":"6","author":"Hirsh","year":"2004","journal-title":"Clinical Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/JTO.0b013e3181651c0e","article-title":"Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity","volume":"3","author":"Hirsh","year":"2008","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.27_suppl.102","article-title":"Association between bisphosphonate use in metastatic breast cancer (MBC) and overall survival","volume":"29","author":"Mathew","year":"2011","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2490-10-23","article-title":"Pathologic fracture and metastatic spinal cord compression in patients with prostate cancer and bone metastases","volume":"10","author":"Nieder","year":"2010","journal-title":"BMC Urology"},{"key":"10.1016\/j.jbo.2012.12.004_bib20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3111\/13696998.2011.649324","article-title":"Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers","volume":"15","author":"Henk","year":"2012","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.jbo.2012.12.004_bib21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF02470635","article-title":"The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer","volume":"17","author":"Osada","year":"1987","journal-title":"The Japanese Journal of Surgery"},{"key":"10.1016\/j.jbo.2012.12.004_bib22","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1378\/chest.97.5.1052","article-title":"Extrathoracic staging of bronchogenic carcinoma","volume":"97","author":"Salvatierra","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.jbo.2012.12.004_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/thx.46.7.469","article-title":"Initial staging of non-small cell lung cancer: value of routine radioisotope bone scanning","volume":"46","author":"Michel","year":"1991","journal-title":"Thorax"},{"key":"10.1016\/j.jbo.2012.12.004_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00003072-199102000-00009","article-title":"A correlation study of bone scanning with clinical and laboratory findings in the staging of nonsmall-cell lung cancer","volume":"16","author":"Tornyos","year":"1991","journal-title":"Clinical Nuclear Medicine"},{"key":"10.1016\/j.jbo.2012.12.004_bib25","first-page":"S45","article-title":"Incidence and distribution of skeletal metastases in NSCLC in the era of PET [abstract]","volume":"46","author":"Kosteva","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11999-007-0051-0","article-title":"Predictors of survival in patients with bone metastasis of lung cancer","volume":"466","author":"Sugiura","year":"2008","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"10.1016\/j.jbo.2012.12.004_bib27","first-page":"5245","article-title":"Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis","volume":"29","author":"Spizzo","year":"2009","journal-title":"Anticancer Research"},{"key":"10.1016\/j.jbo.2012.12.004_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.lungcan.2008.10.026","article-title":"Risk factors for skeletal-related events in patients with non-small cell lung cancer treated by chemotherapy","volume":"65","author":"Sekine","year":"2009","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jbo.2012.12.004_bib29","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.jbo.2012.12.004_bib30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1742-1241.2003.tb10461.x","article-title":"Bone metastasis as the first manifestation of lung cancer","volume":"57","author":"Kagohashi","year":"2003","journal-title":"International Journal of Clinical Practice"},{"key":"10.1016\/j.jbo.2012.12.004_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1634\/theoncologist.2010-0350","article-title":"Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis","volume":"16","author":"Niikura","year":"2011","journal-title":"The Oncologist"},{"key":"10.1016\/j.jbo.2012.12.004_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/bjc.1987.13","article-title":"The clinical course of bone metastases from breast cancer","volume":"55","author":"Coleman","year":"1987","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib33","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/annonc\/mdh089","article-title":"Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis","volume":"15","author":"Ali","year":"2004","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology\/ESMO"},{"key":"10.1016\/j.jbo.2012.12.004_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2012.05.094","article-title":"Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis","author":"Bae","year":"2012","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jbo.2012.12.004_bib36","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/JTO.0b013e3181b68e5a","article-title":"Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel","volume":"4","author":"De Marinis","year":"2009","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8106","article-title":"The impact of zoledronic acid treatment on frequency of skeletal complications experienced and on followup duration post diagnosis of bone metastasis in lung cancer patients","volume":"26","author":"Hatoum","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999\u20132007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.jbo.2012.12.004_bib39","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","article-title":"Skeletal fractures negatively correlate with overall survival in men with prostate cancer","volume":"168","author":"Oefelein","year":"2002","journal-title":"The Journal of Urology"},{"key":"10.1016\/j.jbo.2012.12.004_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e18054","article-title":"Impact of EGFR tyrosine kinase inhibitors on skeletal-related events in EGFR mutation-positive non-small cell lung cancer patients with bone metastases","volume":"30","author":"Yoshida","year":"2012","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib41","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.lungcan.2007.11.002","article-title":"Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib","volume":"60","author":"Zampa","year":"2008","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jbo.2012.12.004_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-004-1720-2","article-title":"A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer","volume":"89","author":"von Minckwitz","year":"2005","journal-title":"Breast Cancer Research and Treatment"},{"key":"10.1016\/j.jbo.2012.12.004_bib43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clon.2011.11.004","article-title":"Update on the systematic review of palliative radiotherapy trials for bone metastases","volume":"24","author":"Chow","year":"2012","journal-title":"Clinical Oncology (Royal College of Radiologists (Great Britain))"},{"key":"10.1016\/j.jbo.2012.12.004_bib44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0360-3016(02)04147-0","article-title":"Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases","volume":"55","author":"Wu","year":"2003","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.jbo.2012.12.004_bib45","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.clon.2005.03.012","article-title":"Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review","volume":"17","author":"Haddad","year":"2005","journal-title":"Clinical Oncology (Royal College of Radiologists (Great Britain))"},{"key":"10.1016\/j.jbo.2012.12.004_bib46","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib47","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jbo.2012.12.004_bib48","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib49","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MED.0b013e32834b4401","article-title":"Mechanisms and treatment of hypercalcemia of malignancy","volume":"18","author":"Clines","year":"2011","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"10.1016\/j.jbo.2012.12.004_bib50","article-title":"Roberta Rondena, Paola Bogani, Carla Ripamonti. ZOOM: a prospective, randomized trial of zoledronic acid (ZOL; q 4 wk vs q 12 wk) for long-term treatment in patients with bone-metastatic breast cancer (BC) after 1yr of standard ZOL treatment","volume":"30","author":"Dino Amadori","year":"2012","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib51","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib52","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib53","first-page":"213","article-title":"A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy","volume":"17","author":"Piga","year":"1998","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"key":"10.1016\/j.jbo.2012.12.004_bib54","first-page":"3133","article-title":"Rapid infusion of ibandronate in lung cancer patients with bone metastases","volume":"26","author":"Kiagia","year":"2006","journal-title":"Anticancer Research"},{"key":"10.1016\/j.jbo.2012.12.004_bib55","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s00432-008-0419-x","article-title":"Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease","volume":"134","author":"Mystakidou","year":"2008","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/MJT.0b013e3181e70c38","article-title":"A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain","volume":"18","author":"Heras","year":"2011","journal-title":"American Journal of Therapeutics"},{"key":"10.1016\/j.jbo.2012.12.004_bib57","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/ijc.24470","article-title":"The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis","volume":"125","author":"Zarogoulidis","year":"2009","journal-title":"International Journal of Cancer Journal International du Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib58","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.lungcan.2009.04.020","article-title":"Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer","volume":"67","author":"Pandya","year":"2010","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jbo.2012.12.004_bib59","doi-asserted-by":"crossref","DOI":"10.1007\/s00520-012-1563-z","article-title":"Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis","author":"Lopez-Olivo","year":"2012","journal-title":"Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"12","key":"10.1016\/j.jbo.2012.12.004_bib60","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib61","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3111\/13696998.2011.650489","article-title":"Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases","volume":"15","author":"Henk","year":"2012","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.jbo.2012.12.004_bib62","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/JTO.0b013e3182199c03","article-title":"Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials","volume":"6","author":"Soo","year":"2011","journal-title":"Journal of Thoracic oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"key":"10.1016\/j.jbo.2012.12.004_bib63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib64","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.jbo.2012.12.004_bib65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.jbo.2012.12.004_bib66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"The Lancet Oncology"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:42Z","timestamp":1761941742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137413000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S2212137413000031"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2012.12.004","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence and consequences of bone metastases in lung cancer patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2012.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}